Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients

REFERENCES

• Ramalingam S, Belani C: Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist. 2008;13(Suppl 1):5–13.
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P, : Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009;27:1227–1234.
   PubMed Web of Science ®Google Scholar
• Williamson SK, Crowley JJ, Lara PN, : Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol. 2005;23:9097–9104.
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S, Yang CH, : Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–957.
   PubMed Web of Science ®Google Scholar
• Maemondo M., Inoue A., Kobayashi K., : Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–2388.
   PubMed Web of Science ®Google Scholar
• Rosell R., Gervais R, Vergnenegre A. Spanish Lung Cancer Group: Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: interim results of the European erlotinib versus chemotherapy (EURTAC) phase III randomized trial. J Clin Oncol. 2011;29:7503.
   Google Scholar
• Zhou CC, Wu YL, Chen GY, : Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735–742.
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Akerley W, Bepler G, : Non-small cell lung cancer. J National Compr Cancer Netw. 2010;8:740–801.
   PubMed Web of Science ®Google Scholar
• Chiarle R, Voena C, Ambrogio C, : The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008;8:11–23.
   PubMed Web of Science ®Google Scholar
• Kwak EL, Bang YJ, Camidge DR, : Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693–1170
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, : MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039–1043.
   PubMed Web of Science ®Google Scholar
• Spigel DR, Ervin TJ, Ramlau R, : Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol. 2011;29:7505.
   Web of Science ®Google Scholar
• Pao W, Wang TY, Riely GJ, : KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005;2:e17.
   PubMed Web of Science ®Google Scholar
• Kris MG, Johnson BE, Kwiatkowki DG, : Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). J Clin Oncol. 2011;29:7506.
   Google Scholar
• Sun Y, Ren Y, Fang Z, : Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol. 2010;28: 4616–4620.
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, : Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–566.
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, : Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–2139.
   PubMed Web of Science ®Google Scholar
• Beau-Faller M, Ruppert AM, Voegeli AC, : MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort. J Thorac Oncol. 2008;3:331–339.
   PubMed Web of Science ®Google Scholar
• Chen HJ, Mok TS, Chen ZH, : Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer. Pathol Oncol Res. 2009;15:651–658.
   PubMed Web of Science ®Google Scholar
• Chen, HQ, Sun, YH, Ren, Y, : Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol. 2010;28:4616–4620.
   PubMed Web of Science ®Google Scholar
• Turke AB, Zejnullahu K, Wu YL, : Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 2010;17:77–88.
   PubMed Web of Science ®Google Scholar
• Benedettini E, Sholl LM, Peyton M, : Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol. 2010;177:415–423.
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Niki T, Goto A, : c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis. Cancer Sci. 2007;98:1006–1013.
   PubMed Web of Science ®Google Scholar
• Okuda K, Sasaki H, Yukiue H, : Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci. 2008;99:2280–2285.
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Marchetti A, Skokan M, : Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol. 2009;27:1667–1674.
   PubMed Web of Science ®Google Scholar
• Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458:719–724.
   PubMed Web of Science ®Google Scholar
• Ren S, Chen X, Kuang P, : Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma. Cancer 2012;118(22):5588–5594.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhang X, Bai H, : EML4-ALK rearrangement and its clinical significance in Chinese patients with advanced non-small cell lung cancer. Oncology. 2012;83(5):248–256.
   PubMed Web of Science ®Google Scholar
• An SJ, Chen ZH, Su J, : Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS One. 2012;7(6):e40109.
   PubMed Web of Science ®Google Scholar
• Li C, Fang R, Sun Y, : Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS One. 2011;6(11):e28204.
   PubMed Web of Science ®Google Scholar
• Shaozhang Z, Xiaomei L, Aiping Z, : Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations. Genes Chromosomes Cancer. 2012;51(10):925–932.
   PubMed Web of Science ®Google Scholar
• Li H, Pan Y, Li Y, : Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. Lung Cancer. 2013;79(1):8–13.
   PubMed Web of Science ®Google Scholar
• Martelli MP, Sozzi G, Hernandez L, : EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol. 2009;174:661–670.
   PubMed Web of Science ®Google Scholar
• Inamura K, Takeuchi K, Togashi Y, : EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008;3:13–17.
   PubMed Web of Science ®Google Scholar
• Rodig SJ, Mino-Kenudson M, Dacic S, : Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009;15:5216–5223.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Yeap BY, Mino-Kenudson M, : Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27:4247–4253.
   PubMed Web of Science ®Google Scholar
• Liu B, Shi SS, Wang X, : Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification. Zhonghua Bing Li Xue Za Zhi. 2012;41(8):505–510.
   PubMedGoogle Scholar
• Zhang Y, Sun Y, Pan Y, : Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Clin Cancer Res. 2012;18:1947–1953.
   PubMed Web of Science ®Google Scholar
• Wang DW, Leung EL, So KK, : The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009;115:1723–1733.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang S, Yang X, : Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer. 2010;9:188.
   PubMed Web of Science ®Google Scholar
• Koivunen JP, Mermel C, Zejnullahu K, : EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008;14:4275–4283.
   PubMed Web of Science ®Google Scholar
• Yamada T, Takeuchi S, Nakade J, : Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. Clin Cancer Res. 2012;18:3592–3602.
   PubMed Web of Science ®Google Scholar
• Sasaki T, Koivunen J, Ogino A, : A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 2011;71:6051–6060.
   PubMed Web of Science ®Google Scholar
• Tanizaki J, Okamoto I, Okamoto K, : MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations. J Thorac Oncol. 2011;6(10):1624–1631.
   PubMed Web of Science ®Google Scholar
• Dziadziuszko R, Wynes MW, Singh S, : Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer. J Thorac Oncol. 2012;7(2):340–347.
   PubMed Web of Science ®Google Scholar
• Kubo T, Yamamoto H, Lockwood WW, : MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int J Cancer. 2009;15;124(8):1778–1784.
   Google Scholar